HRP20161329T1 - Oralni oblici doziranja koji sadrže likarbazepin acetat - Google Patents
Oralni oblici doziranja koji sadrže likarbazepin acetat Download PDFInfo
- Publication number
- HRP20161329T1 HRP20161329T1 HRP20161329TT HRP20161329T HRP20161329T1 HR P20161329 T1 HRP20161329 T1 HR P20161329T1 HR P20161329T T HRP20161329T T HR P20161329TT HR P20161329 T HRP20161329 T HR P20161329T HR P20161329 T1 HRP20161329 T1 HR P20161329T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical preparation
- oral dosage
- preparation
- dosage form
- weight
- Prior art date
Links
- 239000006186 oral dosage form Substances 0.000 title claims 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 title 1
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 238000002360 preparation method Methods 0.000 claims 9
- 239000011230 binding agent Substances 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 5
- 239000007884 disintegrant Substances 0.000 claims 4
- QIALRBLEEWJACW-INIZCTEOSA-N eslicarbazepine acetate Chemical compound CC(=O)O[C@H]1CC2=CC=CC=C2N(C(N)=O)C2=CC=CC=C12 QIALRBLEEWJACW-INIZCTEOSA-N 0.000 claims 4
- 229960003233 eslicarbazepine acetate Drugs 0.000 claims 4
- 238000005469 granulation Methods 0.000 claims 4
- 230000003179 granulation Effects 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000000314 lubricant Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical group [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000005550 wet granulation Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (24)
1. Farmaceutski pripravak koji sadrži eslikarbazepin acetat u kombinaciji s vezivnim sredstvom i sredstvom za raspadanje, naznačen time da su eslikarbazepin acetat i dio u granulama prisutnog sredstva za raspadanje pripremljeni postupkom vlažne granulacije, a preostali dio sredstva za raspadanje je ekstragranuliran, te pri čemu pripravak ima nasipnu gustoću od barem 0.3 g/mL.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da pripravak ima nasipnu gustoću od barem 0.4 g/mL.
3. Farmaceutski pripravak prema zahtjevu 1 ili zahtjevu 2, naznačen time da nadalje sadrži ekstragranularno sredstvo za podmazivanje.
4. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da sredstvo za raspadanje je kroskarmeloza natrij.
5. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time da vezivno sredstvo je povidon.
6. Farmaceutski pripravak naznačen time da se proizvodi od pripravka prema bilo kojem od zahtjeva 1 do 5.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time da pripravak je tableta i ima nasipnu gustoću od 0.5-1.5 g/mL.
8. Farmaceutski pripravak prema zahtjevu 6, naznačen time da ukupna težina pripravka sadrži 0.5-70 tež.% sredstva za raspadanje.
9. Farmaceutski pripravak prema zahtjevu 6, naznačen time da ukupna težina pripravka sadrži 0.5-70 tež.% vezivnog sredstva.
10. Farmaceutski pripravak prema zahtjevu 6, naznačen time da ukupna težina pripravka sadrži 0.1-10 tež.% sredstva za podmazivanje.
11. Uporaba farmaceutskog pripravka prema bilo kojem od zahtjeva 1 do 5 naznačena time da tvori farmaceutski pripravak.
12. Uporaba prema zahtjevu 11, naznačena time da je farmaceutski pripravak tableta ili kapsula.
13. Postupak za pripremanje farmaceutskog pripravka, i proizvoljno oralnog oblika doziranja, koji sadrži vezivno sredstvo i sredstvo za raspadanje, naznačen time da postupak sadrži slijedeće korake:
- miješanje eslikarbazepin acetata s dijelom ukupne količine vezivnog sredstva i dio sredstva za raspadanje;
- osiguravanje granulacijske tekućine;
- otapanje i raspršivanje preostalog udjela ukupne količine vezivnog sredstva u granulacijskoj tekućini;
- granuliranje smjese iz koraka miješanja korištenjem granulacijske tekućine nastale u koraku otapanja i raspršivanja da se dobiju granule;
- dovođenje u kontakt granula s preostalim dijelom sredstva za raspadanje da se dobije pripravak koji ima nasipnu gustoću od barem 0.3 g/mL, te
- proizvoljno formiranje oralnog oblika doziranja.
14. Postupak prema zahtjevu 13, naznačen time da se eslikarbazepin acetat miješa s 20-80 tež.% ukupne količine vezivnog sredstva.
15. Postupak prema zahtjevu 13, naznačen time da je u granulama prisutno 30-70% ukupne količine sredstva za raspadanje.
16. Postupak prema bilo kojem od zahtjeva 13 do 15, naznačen time da granulacijska tekućina je voda, etanol ili njihova smjesa.
17. Postupak prema bilo kojem od zahtjeva 13 do 16, naznačen time da postupak dodatno sadrži korak sušenja granula.
18. Postupak prema bilo kojem od zahtjeva 13 do 17, naznačen time da se pripravak oblikuje u oralni oblik doziranja.
19. Postupak prema zahtjevu 18, naznačen time da se ukupna težina oralnog oblika doziranja sastoji od 0.5-70 tež.% sredstva za raspadanje.
20. Postupak prema zahtjevu 18, naznačen time da se ukupna težina oralnog oblika doziranja sastoji od 0.5-70 tež.% vezivnog sredstva.
21. Postupak prema zahtjevu 18, naznačen time da se ukupna težina oralnog oblika doziranja sastoji od 0.1-10 tež.% sredstva za podmazivanje.
22. Postupak prema bilo kojem od zahtjeva 13 do 21, naznačen time da oralni oblik doziranja je tableta i korak oblikovanja uključuje komprimiranje.
23. Postupak prema zahtjevu 22, naznačen time da tableta ima nasipnu gustoću od 0.5-1.5 g/mL.
24. Postupak prema bilo kojem od zahtjeva 13 do 21, naznačen time da oralni oblik doziranja je oblik kapsule i korak oblikovanja uključuje ispunjavanje kapsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98279007P | 2007-10-26 | 2007-10-26 | |
| EP08842368.6A EP2214636B1 (en) | 2007-10-26 | 2008-10-24 | Oral dosage forms comprising licarbazepine acetate |
| PCT/PT2008/000043 WO2009054743A1 (en) | 2007-10-26 | 2008-10-24 | Oral dosage forms comprising licarbazξpine acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161329T1 true HRP20161329T1 (hr) | 2016-12-02 |
Family
ID=40254311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161329TT HRP20161329T1 (hr) | 2007-10-26 | 2016-10-12 | Oralni oblici doziranja koji sadrže likarbazepin acetat |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US8372431B2 (hr) |
| EP (2) | EP2214636B1 (hr) |
| JP (4) | JP2011500797A (hr) |
| KR (3) | KR20100093057A (hr) |
| CN (1) | CN101848698A (hr) |
| AR (1) | AR069031A1 (hr) |
| AU (1) | AU2008317584B2 (hr) |
| BR (1) | BRPI0818680B1 (hr) |
| CA (1) | CA2703313C (hr) |
| CY (1) | CY1118350T1 (hr) |
| DK (1) | DK2214636T3 (hr) |
| ES (2) | ES2607002T3 (hr) |
| HR (1) | HRP20161329T1 (hr) |
| HU (1) | HUE030788T2 (hr) |
| IL (1) | IL205160A0 (hr) |
| LT (1) | LT2214636T (hr) |
| MX (1) | MX2010004323A (hr) |
| PL (1) | PL2214636T3 (hr) |
| PT (2) | PT2214636T (hr) |
| RS (1) | RS55376B1 (hr) |
| RU (1) | RU2546521C2 (hr) |
| SI (1) | SI2214636T1 (hr) |
| UA (1) | UA110012C2 (hr) |
| WO (1) | WO2009054743A1 (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| RU2563819C2 (ru) | 2009-07-21 | 2015-09-20 | Керикс Байофармасьютикалз, Инк. | Лекарственные формы цитрата железа (iii) |
| CA2769181C (en) | 2009-07-27 | 2017-11-28 | Bial-Portela & Ca., S.A. | Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia |
| HRP20211826T1 (hr) | 2009-10-26 | 2022-03-04 | Merck Sharp & Dohme Corp. | Čvrste farmaceutske kompozicije koje sadrže inhibitor integraze |
| US20120121703A1 (en) * | 2010-07-20 | 2012-05-17 | Japan Tobacco Inc. | Tablet containing ferric citrate |
| TR201008460A1 (tr) * | 2010-10-15 | 2012-05-21 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Eslikarbazepinin saşe formülasyonları. |
| JP6133786B2 (ja) * | 2010-12-31 | 2017-05-24 | ビアル−ポルテラ エ コンパニア，ソシエダッド アノニマ | エスリカルバゼピンアセテート含有顆粒 |
| EP2747770A1 (en) | 2011-08-26 | 2014-07-02 | BIAL - Portela & Cª S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
| EP3103444A1 (en) | 2015-06-09 | 2016-12-14 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical compositions of lacosamide and eslicarbazepine |
| HUE057788T2 (hu) * | 2015-12-18 | 2022-06-28 | Jubilant Generics Ltd | Eslikarbazepin szilárd orális dózisformái |
| UA123552C2 (uk) * | 2016-06-29 | 2021-04-21 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Фармацевтична композиція, що містить комбінацію мемантину і мелатоніну |
| CN106913550B (zh) * | 2017-03-10 | 2019-12-17 | 扬子江药业集团北京海燕药业有限公司 | 一种醋酸艾司利卡西平片的制备方法 |
| WO2019058354A1 (en) * | 2017-09-25 | 2019-03-28 | Jubilant Generics Limited | SUSPENSION OF ESLICARBAZÉPINE |
| US11318145B2 (en) | 2018-09-25 | 2022-05-03 | Jubilant Generics Limited | Eslicarbazepine suspension |
| EA037195B1 (ru) * | 2018-03-28 | 2021-02-18 | Акционерное Общество "Химфарм" | Биологически активная добавка для улучшения функционального состояния дыхательной системы и восстановления иммунной системы (варианты) |
| US20220127567A1 (en) | 2018-09-14 | 2022-04-28 | Keio University | Method for producing astrocytes |
| HUP1900153A1 (hu) | 2019-05-14 | 2020-11-30 | Meditop Gyogyszeripari Kft | Eszlikarbazepin-acetát tartalmú granulátum, ennek elõállítása, ezt tartalmazó egyéb gyógyszerkészítmények, és ezek alkalmazása |
| US20210346324A1 (en) * | 2020-05-05 | 2021-11-11 | NeuroBo Therapeutics, Inc. | Niclosamide Formulations and Methods of Use |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5326570A (en) * | 1991-07-23 | 1994-07-05 | Pharmavene, Inc. | Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine |
| ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| US6296873B1 (en) * | 1997-01-23 | 2001-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Zero-order sustained release delivery system for carbamazephine derivatives |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9721497D0 (en) | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
| US6475510B1 (en) * | 1997-12-19 | 2002-11-05 | Smithkline Beecham Corporation | Process for manufacturing bite-dispersion tablets |
| SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| IN190699B (hr) * | 2001-02-02 | 2003-08-16 | Sun Pharmaceutical Ind Ltd | |
| GB0111566D0 (en) | 2001-05-11 | 2001-07-04 | Portela & Ca Sa | Method for preparation of (s)-(+)-and (r)-(-)-10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azephine-5-carboxamide |
| GB0112812D0 (en) | 2001-05-25 | 2001-07-18 | Portela & Ca Sa | Mthd for preparation of 10, 11-dihydro-10-hydroxy-5H-dibenz/B,F/azepine-5-c arboxamide and 10,11-dihydro-10-oxo-5H-dibenz/B,F/azepine-5-carb oxamide therefrom |
| AU2003231919A1 (en) * | 2002-03-14 | 2003-09-22 | Sun Pharmaceutical Industries Limited | Oral controlled drug delivery system containing carbamazepine |
| DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
| MXPA04011801A (es) | 2002-05-31 | 2005-09-12 | Desitin Arzneimittel Gmbh | Composicion farmaceutica que contiene oxcarbazepina con liberacion controlada de la substancia activa. |
| DE10230027A1 (de) | 2002-07-04 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen auf der Basis von Natriumkanalblockern und Magnesiumsalzen |
| GB0221956D0 (en) | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
| BR0315374A (pt) | 2002-10-17 | 2005-08-23 | Novartis Ag | Compostos orgânicos |
| US20040087642A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
| GB2401605A (en) | 2003-05-12 | 2004-11-17 | Portela & Ca Sa | Method for racemisation of (S)-(+)- and (R)-(-)-10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide and optically enriched mixtures thereof |
| US20070196396A1 (en) * | 2004-02-11 | 2007-08-23 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| US7956140B2 (en) | 2004-03-17 | 2011-06-07 | Dsm Ip Assets B.V. | Polymerization catalyst comprising amidine ligand |
| AR048318A1 (es) * | 2004-03-22 | 2006-04-19 | Novartis Ag | Formulaciones de matriz orales que comprenden licarbazepina |
| AR048672A1 (es) | 2004-03-22 | 2006-05-17 | Novartis Ag | Tabletas de desintegracion que comprenden licarbazepina |
| GB2416167A (en) | 2004-07-13 | 2006-01-18 | Portela & Ca Sa | Chiral inversion and esterification of (S)- and (R)-10-hydroxy-dibenzazepine carboxamides |
| EP2098223A1 (en) | 2004-11-10 | 2009-09-09 | Teva Pharmaceutical Industries Ltd. | Compressed solid dosage form |
| GB0425320D0 (en) | 2004-11-17 | 2004-12-22 | Johnson Matthey Plc | Diamines |
| GB2422149A (en) | 2005-01-14 | 2006-07-19 | Portela & Ca Sa | Process for the preparation of 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| PT2380575E (pt) | 2005-05-06 | 2015-06-17 | Bial Portela & Ca Sa | Acetato de eslicarbazepina e utilização |
| AU2005331690C1 (en) | 2005-05-06 | 2013-01-17 | Bial-Portela & Ca, S.A. | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| US8059672B2 (en) | 2005-05-18 | 2011-11-15 | Sprint Communications Company L.P. | Internet communications between wireless base stations and service nodes |
| US20070071819A1 (en) * | 2005-05-30 | 2007-03-29 | Kesarwani Amit K | Multiple unit modified release compositions of carbamazepine and process for their preparation |
| WO2007008576A2 (en) | 2005-07-08 | 2007-01-18 | Taro Pharmaceuticals U.S.A., Inc. | Oxcarbazepine formulation |
| GB0515690D0 (en) | 2005-07-29 | 2005-09-07 | Portela & Ca Sa | Asymmetric catalytic reduction |
| WO2007029093A2 (en) | 2005-09-05 | 2007-03-15 | Ranbaxy Laboratories Limited | Pharmaceutical dosage forms of oxcarbazepine |
| CA2634879A1 (en) | 2006-01-31 | 2007-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations of oxcarbazepine and methods for its preparation |
| EP1815849A1 (en) | 2006-01-31 | 2007-08-08 | Teva Pharmaceutical Industries Ltd | Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution |
| GB0603008D0 (en) | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
| WO2008037044A1 (en) | 2006-09-27 | 2008-04-03 | Medley S.A. Indústria Farmacêutica | Oxcarbazepine-containing oral formulation and a process to obtain the same |
| US20080138403A1 (en) | 2006-12-08 | 2008-06-12 | Sun Pharmaceutical Industries Ltd. | Pharmaceutical dosage forms of oxcarbazepine |
| US8372431B2 (en) | 2007-10-26 | 2013-02-12 | Bial-Portela & C.A., S.A. | Pharmaceutical composition comprising licarbazepine acetate |
| HUE057788T2 (hu) | 2015-12-18 | 2022-06-28 | Jubilant Generics Ltd | Eslikarbazepin szilárd orális dózisformái |
-
2008
- 2008-10-23 US US12/257,240 patent/US8372431B2/en active Active
- 2008-10-24 BR BRPI0818680-4A patent/BRPI0818680B1/pt not_active IP Right Cessation
- 2008-10-24 AU AU2008317584A patent/AU2008317584B2/en active Active
- 2008-10-24 ES ES08842368.6T patent/ES2607002T3/es active Active
- 2008-10-24 UA UAA201006417A patent/UA110012C2/ru unknown
- 2008-10-24 AR ARP080104652A patent/AR069031A1/es unknown
- 2008-10-24 PL PL08842368T patent/PL2214636T3/pl unknown
- 2008-10-24 KR KR1020107011233A patent/KR20100093057A/ko active Application Filing
- 2008-10-24 JP JP2010530951A patent/JP2011500797A/ja active Pending
- 2008-10-24 PT PT88423686T patent/PT2214636T/pt unknown
- 2008-10-24 RU RU2010121135/15A patent/RU2546521C2/ru active
- 2008-10-24 KR KR1020187037643A patent/KR102116087B1/ko active IP Right Grant
- 2008-10-24 PT PT161806872T patent/PT3202392T/pt unknown
- 2008-10-24 ES ES16180687T patent/ES2898202T3/es active Active
- 2008-10-24 EP EP08842368.6A patent/EP2214636B1/en active Active
- 2008-10-24 HU HUE08842368A patent/HUE030788T2/en unknown
- 2008-10-24 MX MX2010004323A patent/MX2010004323A/es active IP Right Grant
- 2008-10-24 EP EP16180687.2A patent/EP3202392B1/en active Active
- 2008-10-24 KR KR1020167036806A patent/KR20170004034A/ko active Search and Examination
- 2008-10-24 CA CA2703313A patent/CA2703313C/en active Active
- 2008-10-24 SI SI200831687A patent/SI2214636T1/sl unknown
- 2008-10-24 LT LTEP08842368.6T patent/LT2214636T/lt unknown
- 2008-10-24 CN CN200880112983A patent/CN101848698A/zh active Pending
- 2008-10-24 WO PCT/PT2008/000043 patent/WO2009054743A1/en active Application Filing
- 2008-10-24 DK DK08842368.6T patent/DK2214636T3/en active
- 2008-10-24 RS RS20160895A patent/RS55376B1/sr unknown
-
2010
- 2010-04-18 IL IL205160A patent/IL205160A0/en unknown
-
2013
- 2013-01-30 US US13/754,439 patent/US20130150348A1/en not_active Abandoned
- 2013-12-17 US US14/108,615 patent/US9566244B2/en active Active
-
2014
- 2014-07-10 JP JP2014141894A patent/JP6043758B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-27 JP JP2016147183A patent/JP2017014233A/ja active Pending
- 2016-10-12 HR HRP20161329TT patent/HRP20161329T1/hr unknown
- 2016-12-14 CY CY20161101294T patent/CY1118350T1/el unknown
-
2017
- 2017-01-04 US US15/397,945 patent/US10912781B2/en active Active
-
2018
- 2018-06-26 JP JP2018120334A patent/JP2018172407A/ja active Pending
-
2021
- 2021-01-29 US US17/248,581 patent/US20210322436A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161329T1 (hr) | Oralni oblici doziranja koji sadrže likarbazepin acetat | |
| ES2517244T3 (es) | Forma farmacéutica hinchable que comprende goma gellan | |
| HRP20161262T1 (hr) | Tablete ulipristal acetata | |
| HRP20100674T1 (hr) | Farmaceutski pripravak koji sadrzi omega-karboksiaril supstituirani difenil ureu za lijecenje raka | |
| RU2000109583A (ru) | Твердая дозированная лекарственная форма для орального применения, содержащая комбинацию метформина и глибенкламида | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| US20090317465A1 (en) | Composition and method of preparation of release systems for constant (zero-order) release of active agents | |
| RU2016152167A (ru) | Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения | |
| CN105142618A (zh) | 提供药理及临床效应的莫沙必利每日单次施用缓释制剂 | |
| JP2012031131A5 (hr) | ||
| JP2011500797A5 (hr) | ||
| JP2014237658A5 (hr) | ||
| HRP20190550T1 (hr) | Formule i metode proizvodnje formulacija za upotrebu u pražnjenju debelog crijeva | |
| JP2012031147A5 (hr) | ||
| CN102438597A (zh) | 一种选自中枢性作用肌弛缓药类型的化合物的新型缓释制剂 | |
| JP2012502061A5 (hr) | ||
| Sokar et al. | Pulsatile core-in-cup valsartan tablet formulations: in vitro evaluation | |
| WO2007134158A3 (en) | Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy | |
| JP2013536821A (ja) | 活性化合物含有顆粒及び投与剤形の調製における、アミノ含有ポリマーに基づくコポリマーのマトリックス結合剤としての使用 | |
| HRP20141134T1 (hr) | Kruta farmaceutska formulacija | |
| WO2009038145A1 (ja) | 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法 | |
| CA2696977A1 (en) | Improved pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof | |
| JPH06321790A (ja) | 速崩壊性生薬製剤 | |
| JP6160263B2 (ja) | ロキソプロフェン含有医薬組成物 | |
| CN102440963A (zh) | 一种别嘌醇缓释微丸及其制备方法 |